FINWIRES · TerminalLIVE
FINWIRES

$RCUS

4 stories mentioning RCUSUpdated 16d ago

Every FINWIRES story that references RCUS, newest first.

Insider Trading

Arcus Biosciences Insider Sold Shares Worth $2,031,919, According to a Recent SEC Filing

Juan C. Jaen, President, on July 09, 2026, sold 68,569 shares in Arcus Biosciences (RCUS) for $2,031,919. Following the Form 4 filing with the SEC, Jaen has control over a total of 1,200,531 common shares of the company, with 378,291 shares held directly and 822,240 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1724521/000142299626000006/xslF345X05/wk-form4_1783978603.xml

$RCUS
Insider Trading

Arcus Biosciences Insider Sold Shares Worth $877,501, According to a Recent SEC Filing

Juan C. Jaen, President, on June 22, 2026, sold 31,431 shares in Arcus Biosciences (RCUS) for $877,501. Following the Form 4 filing with the SEC, Jaen has control over a total of 1,269,100 common shares of the company, with 378,291 shares held directly and 890,809 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1724521/000161071726000294/xslF345X05/form4.xml

$RCUS
Wire

Arcus Biosciences Has Favorable Setup After Merck Belzutifan Failure, Wedbush Says

Arcus Biosciences (RCUS) shares have a favorable setup following Merck's (MRK) belzutifan phase 3 failure in Litespark-012, with Wedbush Securities saying the readout does not represent negative readthrough for Arcus' casdatifan and highlights a differentiated profile in clear cell renal cell carcinoma, or RCC.The brokerage said in a Tuesday note that the Merck data do not impact Arcus' TKI-free frontline strategy and that casdatifan remains supported by a more optimal development approach and stronger comparative efficacy versus belzutifan.Wedbush also said recent weakness following the discontinuation of Arcus' domvanalimab program has created an attractive entry point ahead of upcoming clinical data readouts, reinforcing a favorable setup for the stock.The firm reiterated its outperform rating on the stock and price target of $41 per share.Price: $23.31, Change: $+0.57, Percent Change: +2.51%

$MRK$RCUS
Wire

Arcus Biosciences Discontinues Phase 3 Lung Cancer Trial for Futility

Arcus Biosciences (RCUS) said Monday it discontinued its phase 3 STAR-121 study in metastatic non-small cell lung cancer after an Independent Data Monitoring Committee recommended stopping the trial for futility.The study, conducted in collaboration with Gilead Sciences (GILD), evaluated domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab plus chemotherapy as a first-line treatment, the company said.The decision followed a pre-planned futility analysis indicating the treatment was unlikely to meet its primary endpoint.Shares of Arcus Biosciences were down 5% in Monday trading.Price: $23.05, Change: $-1.20, Percent Change: -4.95%

$GILD$RCUS

Track with the FINWIRES app suite

FolioX
FolioX
Track RCUS in your portfolio
WheelAI
WheelAI
Analyze RCUS options with the wheel strategy
StockInsider
StockInsider
See market sentiment on RCUS